+Follow
PanJX
No personal profile
3
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
PanJX
03-07
Novo Valuation Surpasses Tesla on Experimental Obesity Drug Data
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":3573951986254249,"uuid":"3573951986254249","gmtCreate":1610878993591,"gmtModify":1610878993591,"name":"PanJX","pinyin":"panjx","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":3,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.86%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.23","exceedPercentage":"93.01%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":8,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":281792506593432,"gmtCreate":1709825510496,"gmtModify":1709825732270,"author":{"id":"3573951986254249","authorId":"3573951986254249","name":"PanJX","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"","listText":"","text":"","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/281792506593432","repostId":"2417624937","repostType":2,"repost":{"id":"2417624937","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1709853900,"share":"https://www.laohu8.com/m/news/2417624937?lang=&edition=full","pubTime":"2024-03-08 07:25","market":"us","language":"en","title":"Novo Valuation Surpasses Tesla on Experimental Obesity Drug Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2417624937","media":"Reuters","summary":"COPENHAGEN, March 7 (Reuters) - Novo Nordisk on Thursday surpassed Tesla Inc in market valuation after the maker of the popular weight-loss drug Wegovy announced positive early trial data for a highly","content":"<html><head></head><body><p>COPENHAGEN, March 7 (Reuters) - Novo Nordisk on Thursday surpassed Tesla Inc in market valuation after the maker of the popular weight-loss drug Wegovy announced positive early trial data for a highly anticipated new obesity drug.</p><p>Shares surged more than 8% to record highs, shooting Novo Nordisk up in global rankings to the 12th most valuable company from 14 previously, after it told investors a Phase I trial of the pill version of experimental drug amycretin showed participants lost 13.1% of their weight after 12 weeks.</p><p>That compares to a weight loss of about 6% after 12 weeks and 15% after 68 weeks in trials for Wegovy, its blockbuster obesity drug.</p><p>Investors welcomed the news as indicating Novo had more in its pipeline beyond its hugely successful Wegovy. Its shares have soared since launching the weekly injections in the United States in 2021.</p><p>Novo's shares have risen more than three-fold since June 2021 when it launched Wegovy in the United States, last year becoming Europe's most valuable listed company, ahead of LVMH.</p><p>On Thursday, its market valuation reached $606 billion, ahead of Tesla and Visa, according to LSEG data.</p><p>"Novo has made clear that the amycretin molecule likely will form the foundation of the company's rapidly growing pipeline," said Guggenheim analyst Seamus Fernandez.</p><p>Nearly half of Novo's current valuation is based on the company's pipeline of new experimental drugs such as amycretin, according to calculations by Berenberg analysts last week.</p><p>Markus Manns, a portfolio manager at Union Investment in Germany and Novo shareholder, said the early read-out also compared favourably with other weight-loss pills in development, such as rival Eli Lilly's orforglipron.</p><p>Lilly's mid-stage trial showed its experimental pill led to 14.7% weight loss after 36 weeks for people who were obese or overweight.</p><p>The U.S. drugmaker's shares slipped on the upbeat Novo update while shares in Zealand Pharma, which is testing a similar treatment, jumped more than 9%.</p><p>Wegovy belongs to a class of drugs known as GLP-1 agonists, originally designed to treat type 2 diabetes, that have been shown to reduce food cravings and empty the stomach more slowly.</p><p>Following the success of these drugs, companies are working on other promising weight-loss therapies such as amycretin which targets a hormone called amylin in the pancreas that affects hunger.</p><p>Wegovy was the first of a new group of highly effective weight-loss drugs to be launched. Novo and Lilly are so far the leaders in the obesity drug market, forecast by analysts to be worth $100 billion by 2030.</p><h2 id=\"id_3866400247\" style=\"text-align: start;\">HEART DISEASE</h2><p>Novo Nordisk Chief Executive Lars Fruergaard Jorgensen said the obesity drug roll-out will be dominated by injectable medicines, with oral versions introduced later in higher-priced markets. Pills require large amounts of active ingredients, making them costly to produce.</p><p>Earlier in the day, he also announced the company was expanding its focus on diabetes and weight-loss therapies to include cardiovascular disease treatments.</p><p>The change comes after the drugmaker last August said a large study had shown Wegovy also had a clear cardiovascular benefit, boosting efforts by the company to move Wegovy beyond its image as a lifestyle drug.</p><p>"Any company that is so heavily exposed to one therapeutic area needs to try to develop other pillars to stand on," said Wolfgang Lickl, portfolio manager at KB-Vermögensverwaltung.</p><p>"The sheer success in diabetes and obesity will make that difficult, but the cardiovascular field makes sense because of the many synergies," he said.</p><p>Following the August trial, Novo has been trying to convince sceptical medical insurers that the long-term benefits of Wegovy are enough to reduce the overall burden on healthcare systems and the cost of treating heart disease in overweight and obese people.</p><p>It expects Wegovy to be approved for sale in China as soon as this year, which would be its second-biggest market after the United States.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Valuation Surpasses Tesla on Experimental Obesity Drug Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Valuation Surpasses Tesla on Experimental Obesity Drug Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-03-08 07:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>COPENHAGEN, March 7 (Reuters) - Novo Nordisk on Thursday surpassed Tesla Inc in market valuation after the maker of the popular weight-loss drug Wegovy announced positive early trial data for a highly anticipated new obesity drug.</p><p>Shares surged more than 8% to record highs, shooting Novo Nordisk up in global rankings to the 12th most valuable company from 14 previously, after it told investors a Phase I trial of the pill version of experimental drug amycretin showed participants lost 13.1% of their weight after 12 weeks.</p><p>That compares to a weight loss of about 6% after 12 weeks and 15% after 68 weeks in trials for Wegovy, its blockbuster obesity drug.</p><p>Investors welcomed the news as indicating Novo had more in its pipeline beyond its hugely successful Wegovy. Its shares have soared since launching the weekly injections in the United States in 2021.</p><p>Novo's shares have risen more than three-fold since June 2021 when it launched Wegovy in the United States, last year becoming Europe's most valuable listed company, ahead of LVMH.</p><p>On Thursday, its market valuation reached $606 billion, ahead of Tesla and Visa, according to LSEG data.</p><p>"Novo has made clear that the amycretin molecule likely will form the foundation of the company's rapidly growing pipeline," said Guggenheim analyst Seamus Fernandez.</p><p>Nearly half of Novo's current valuation is based on the company's pipeline of new experimental drugs such as amycretin, according to calculations by Berenberg analysts last week.</p><p>Markus Manns, a portfolio manager at Union Investment in Germany and Novo shareholder, said the early read-out also compared favourably with other weight-loss pills in development, such as rival Eli Lilly's orforglipron.</p><p>Lilly's mid-stage trial showed its experimental pill led to 14.7% weight loss after 36 weeks for people who were obese or overweight.</p><p>The U.S. drugmaker's shares slipped on the upbeat Novo update while shares in Zealand Pharma, which is testing a similar treatment, jumped more than 9%.</p><p>Wegovy belongs to a class of drugs known as GLP-1 agonists, originally designed to treat type 2 diabetes, that have been shown to reduce food cravings and empty the stomach more slowly.</p><p>Following the success of these drugs, companies are working on other promising weight-loss therapies such as amycretin which targets a hormone called amylin in the pancreas that affects hunger.</p><p>Wegovy was the first of a new group of highly effective weight-loss drugs to be launched. Novo and Lilly are so far the leaders in the obesity drug market, forecast by analysts to be worth $100 billion by 2030.</p><h2 id=\"id_3866400247\" style=\"text-align: start;\">HEART DISEASE</h2><p>Novo Nordisk Chief Executive Lars Fruergaard Jorgensen said the obesity drug roll-out will be dominated by injectable medicines, with oral versions introduced later in higher-priced markets. Pills require large amounts of active ingredients, making them costly to produce.</p><p>Earlier in the day, he also announced the company was expanding its focus on diabetes and weight-loss therapies to include cardiovascular disease treatments.</p><p>The change comes after the drugmaker last August said a large study had shown Wegovy also had a clear cardiovascular benefit, boosting efforts by the company to move Wegovy beyond its image as a lifestyle drug.</p><p>"Any company that is so heavily exposed to one therapeutic area needs to try to develop other pillars to stand on," said Wolfgang Lickl, portfolio manager at KB-Vermögensverwaltung.</p><p>"The sheer success in diabetes and obesity will make that difficult, but the cardiovascular field makes sense because of the many synergies," he said.</p><p>Following the August trial, Novo has been trying to convince sceptical medical insurers that the long-term benefits of Wegovy are enough to reduce the overall burden on healthcare systems and the cost of treating heart disease in overweight and obese people.</p><p>It expects Wegovy to be approved for sale in China as soon as this year, which would be its second-biggest market after the United States.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4574":"无人驾驶","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","BK4551":"寇图资本持仓","LU1429558221.USD":"Natixis Loomis Sayles US Growth Equity RA USD","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU0823411888.USD":"法巴消费创新基金 Cap","LU1435385759.SGD":"Natixis Loomis Sayles US Growth Equity RA SGD-H","LU0082616367.USD":"摩根大通美国科技A（dist）","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0056508442.USD":"贝莱德世界科技基金A2","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU0719512351.SGD":"JPMorgan Funds - US Technology A (acc) SGD","TSLA":"特斯拉","BK4099":"汽车制造商","BK4548":"巴美列捷福持仓","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU2249611893.SGD":"BNP PARIBAS ENERGY TRANSITION \"CRH\" (SGD) ACC","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","LU2063271972.USD":"富兰克林创新领域基金","BK4550":"红杉资本持仓","LU0823414478.USD":"法巴经典能源转换基金","BK4592":"伊斯兰概念","V":"Visa","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU2326559502.SGD":"Natixis Loomis Sayles US Growth Equity P/A SGD-H","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU1852331112.SGD":"Blackrock World Technology Fund A2 SGD-H","BK4534":"瑞士信贷持仓","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","LU1861215975.USD":"贝莱德新一代科技基金 A2","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1548497426.USD":"安联环球人工智能AT Acc","LU1861558580.USD":"日兴方舟颠覆性创新基金B","LU1861220033.SGD":"Blackrock Next Generation Technology A2 SGD-H","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","NVO":"诺和诺德","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","BK4588":"碎股","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC"},"source_url":"https://news.google.com/rss/articles/CBMilgFodHRwczovL3d3dy5yZXV0ZXJzLmNvbS9idXNpbmVzcy9oZWFsdGhjYXJlLXBoYXJtYWNldXRpY2Fscy9ub3ZvLW5vcmRpc2stcHJlc2VudC1lYXJseS1zdGFnZS10cmlhbC1kYXRhLW5ldy1kaWFiZXRlcy1kcnVnLWludmVzdG9yLW1lZXRpbmctMjAyNC0wMy0wNy_SAQA?oc=5","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2417624937","content_text":"COPENHAGEN, March 7 (Reuters) - Novo Nordisk on Thursday surpassed Tesla Inc in market valuation after the maker of the popular weight-loss drug Wegovy announced positive early trial data for a highly anticipated new obesity drug.Shares surged more than 8% to record highs, shooting Novo Nordisk up in global rankings to the 12th most valuable company from 14 previously, after it told investors a Phase I trial of the pill version of experimental drug amycretin showed participants lost 13.1% of their weight after 12 weeks.That compares to a weight loss of about 6% after 12 weeks and 15% after 68 weeks in trials for Wegovy, its blockbuster obesity drug.Investors welcomed the news as indicating Novo had more in its pipeline beyond its hugely successful Wegovy. Its shares have soared since launching the weekly injections in the United States in 2021.Novo's shares have risen more than three-fold since June 2021 when it launched Wegovy in the United States, last year becoming Europe's most valuable listed company, ahead of LVMH.On Thursday, its market valuation reached $606 billion, ahead of Tesla and Visa, according to LSEG data.\"Novo has made clear that the amycretin molecule likely will form the foundation of the company's rapidly growing pipeline,\" said Guggenheim analyst Seamus Fernandez.Nearly half of Novo's current valuation is based on the company's pipeline of new experimental drugs such as amycretin, according to calculations by Berenberg analysts last week.Markus Manns, a portfolio manager at Union Investment in Germany and Novo shareholder, said the early read-out also compared favourably with other weight-loss pills in development, such as rival Eli Lilly's orforglipron.Lilly's mid-stage trial showed its experimental pill led to 14.7% weight loss after 36 weeks for people who were obese or overweight.The U.S. drugmaker's shares slipped on the upbeat Novo update while shares in Zealand Pharma, which is testing a similar treatment, jumped more than 9%.Wegovy belongs to a class of drugs known as GLP-1 agonists, originally designed to treat type 2 diabetes, that have been shown to reduce food cravings and empty the stomach more slowly.Following the success of these drugs, companies are working on other promising weight-loss therapies such as amycretin which targets a hormone called amylin in the pancreas that affects hunger.Wegovy was the first of a new group of highly effective weight-loss drugs to be launched. Novo and Lilly are so far the leaders in the obesity drug market, forecast by analysts to be worth $100 billion by 2030.HEART DISEASENovo Nordisk Chief Executive Lars Fruergaard Jorgensen said the obesity drug roll-out will be dominated by injectable medicines, with oral versions introduced later in higher-priced markets. Pills require large amounts of active ingredients, making them costly to produce.Earlier in the day, he also announced the company was expanding its focus on diabetes and weight-loss therapies to include cardiovascular disease treatments.The change comes after the drugmaker last August said a large study had shown Wegovy also had a clear cardiovascular benefit, boosting efforts by the company to move Wegovy beyond its image as a lifestyle drug.\"Any company that is so heavily exposed to one therapeutic area needs to try to develop other pillars to stand on,\" said Wolfgang Lickl, portfolio manager at KB-Vermögensverwaltung.\"The sheer success in diabetes and obesity will make that difficult, but the cardiovascular field makes sense because of the many synergies,\" he said.Following the August trial, Novo has been trying to convince sceptical medical insurers that the long-term benefits of Wegovy are enough to reduce the overall burden on healthcare systems and the cost of treating heart disease in overweight and obese people.It expects Wegovy to be approved for sale in China as soon as this year, which would be its second-biggest market after the United States.","news_type":1},"isVote":1,"tweetType":1,"viewCount":43,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":281792506593432,"gmtCreate":1709825510496,"gmtModify":1709825732270,"author":{"id":"3573951986254249","authorId":"3573951986254249","name":"PanJX","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"","listText":"","text":"","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/281792506593432","repostId":"2417624937","repostType":2,"repost":{"id":"2417624937","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1709853900,"share":"https://www.laohu8.com/m/news/2417624937?lang=&edition=full","pubTime":"2024-03-08 07:25","market":"us","language":"en","title":"Novo Valuation Surpasses Tesla on Experimental Obesity Drug Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2417624937","media":"Reuters","summary":"COPENHAGEN, March 7 (Reuters) - Novo Nordisk on Thursday surpassed Tesla Inc in market valuation after the maker of the popular weight-loss drug Wegovy announced positive early trial data for a highly","content":"<html><head></head><body><p>COPENHAGEN, March 7 (Reuters) - Novo Nordisk on Thursday surpassed Tesla Inc in market valuation after the maker of the popular weight-loss drug Wegovy announced positive early trial data for a highly anticipated new obesity drug.</p><p>Shares surged more than 8% to record highs, shooting Novo Nordisk up in global rankings to the 12th most valuable company from 14 previously, after it told investors a Phase I trial of the pill version of experimental drug amycretin showed participants lost 13.1% of their weight after 12 weeks.</p><p>That compares to a weight loss of about 6% after 12 weeks and 15% after 68 weeks in trials for Wegovy, its blockbuster obesity drug.</p><p>Investors welcomed the news as indicating Novo had more in its pipeline beyond its hugely successful Wegovy. Its shares have soared since launching the weekly injections in the United States in 2021.</p><p>Novo's shares have risen more than three-fold since June 2021 when it launched Wegovy in the United States, last year becoming Europe's most valuable listed company, ahead of LVMH.</p><p>On Thursday, its market valuation reached $606 billion, ahead of Tesla and Visa, according to LSEG data.</p><p>"Novo has made clear that the amycretin molecule likely will form the foundation of the company's rapidly growing pipeline," said Guggenheim analyst Seamus Fernandez.</p><p>Nearly half of Novo's current valuation is based on the company's pipeline of new experimental drugs such as amycretin, according to calculations by Berenberg analysts last week.</p><p>Markus Manns, a portfolio manager at Union Investment in Germany and Novo shareholder, said the early read-out also compared favourably with other weight-loss pills in development, such as rival Eli Lilly's orforglipron.</p><p>Lilly's mid-stage trial showed its experimental pill led to 14.7% weight loss after 36 weeks for people who were obese or overweight.</p><p>The U.S. drugmaker's shares slipped on the upbeat Novo update while shares in Zealand Pharma, which is testing a similar treatment, jumped more than 9%.</p><p>Wegovy belongs to a class of drugs known as GLP-1 agonists, originally designed to treat type 2 diabetes, that have been shown to reduce food cravings and empty the stomach more slowly.</p><p>Following the success of these drugs, companies are working on other promising weight-loss therapies such as amycretin which targets a hormone called amylin in the pancreas that affects hunger.</p><p>Wegovy was the first of a new group of highly effective weight-loss drugs to be launched. Novo and Lilly are so far the leaders in the obesity drug market, forecast by analysts to be worth $100 billion by 2030.</p><h2 id=\"id_3866400247\" style=\"text-align: start;\">HEART DISEASE</h2><p>Novo Nordisk Chief Executive Lars Fruergaard Jorgensen said the obesity drug roll-out will be dominated by injectable medicines, with oral versions introduced later in higher-priced markets. Pills require large amounts of active ingredients, making them costly to produce.</p><p>Earlier in the day, he also announced the company was expanding its focus on diabetes and weight-loss therapies to include cardiovascular disease treatments.</p><p>The change comes after the drugmaker last August said a large study had shown Wegovy also had a clear cardiovascular benefit, boosting efforts by the company to move Wegovy beyond its image as a lifestyle drug.</p><p>"Any company that is so heavily exposed to one therapeutic area needs to try to develop other pillars to stand on," said Wolfgang Lickl, portfolio manager at KB-Vermögensverwaltung.</p><p>"The sheer success in diabetes and obesity will make that difficult, but the cardiovascular field makes sense because of the many synergies," he said.</p><p>Following the August trial, Novo has been trying to convince sceptical medical insurers that the long-term benefits of Wegovy are enough to reduce the overall burden on healthcare systems and the cost of treating heart disease in overweight and obese people.</p><p>It expects Wegovy to be approved for sale in China as soon as this year, which would be its second-biggest market after the United States.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Valuation Surpasses Tesla on Experimental Obesity Drug Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Valuation Surpasses Tesla on Experimental Obesity Drug Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-03-08 07:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>COPENHAGEN, March 7 (Reuters) - Novo Nordisk on Thursday surpassed Tesla Inc in market valuation after the maker of the popular weight-loss drug Wegovy announced positive early trial data for a highly anticipated new obesity drug.</p><p>Shares surged more than 8% to record highs, shooting Novo Nordisk up in global rankings to the 12th most valuable company from 14 previously, after it told investors a Phase I trial of the pill version of experimental drug amycretin showed participants lost 13.1% of their weight after 12 weeks.</p><p>That compares to a weight loss of about 6% after 12 weeks and 15% after 68 weeks in trials for Wegovy, its blockbuster obesity drug.</p><p>Investors welcomed the news as indicating Novo had more in its pipeline beyond its hugely successful Wegovy. Its shares have soared since launching the weekly injections in the United States in 2021.</p><p>Novo's shares have risen more than three-fold since June 2021 when it launched Wegovy in the United States, last year becoming Europe's most valuable listed company, ahead of LVMH.</p><p>On Thursday, its market valuation reached $606 billion, ahead of Tesla and Visa, according to LSEG data.</p><p>"Novo has made clear that the amycretin molecule likely will form the foundation of the company's rapidly growing pipeline," said Guggenheim analyst Seamus Fernandez.</p><p>Nearly half of Novo's current valuation is based on the company's pipeline of new experimental drugs such as amycretin, according to calculations by Berenberg analysts last week.</p><p>Markus Manns, a portfolio manager at Union Investment in Germany and Novo shareholder, said the early read-out also compared favourably with other weight-loss pills in development, such as rival Eli Lilly's orforglipron.</p><p>Lilly's mid-stage trial showed its experimental pill led to 14.7% weight loss after 36 weeks for people who were obese or overweight.</p><p>The U.S. drugmaker's shares slipped on the upbeat Novo update while shares in Zealand Pharma, which is testing a similar treatment, jumped more than 9%.</p><p>Wegovy belongs to a class of drugs known as GLP-1 agonists, originally designed to treat type 2 diabetes, that have been shown to reduce food cravings and empty the stomach more slowly.</p><p>Following the success of these drugs, companies are working on other promising weight-loss therapies such as amycretin which targets a hormone called amylin in the pancreas that affects hunger.</p><p>Wegovy was the first of a new group of highly effective weight-loss drugs to be launched. Novo and Lilly are so far the leaders in the obesity drug market, forecast by analysts to be worth $100 billion by 2030.</p><h2 id=\"id_3866400247\" style=\"text-align: start;\">HEART DISEASE</h2><p>Novo Nordisk Chief Executive Lars Fruergaard Jorgensen said the obesity drug roll-out will be dominated by injectable medicines, with oral versions introduced later in higher-priced markets. Pills require large amounts of active ingredients, making them costly to produce.</p><p>Earlier in the day, he also announced the company was expanding its focus on diabetes and weight-loss therapies to include cardiovascular disease treatments.</p><p>The change comes after the drugmaker last August said a large study had shown Wegovy also had a clear cardiovascular benefit, boosting efforts by the company to move Wegovy beyond its image as a lifestyle drug.</p><p>"Any company that is so heavily exposed to one therapeutic area needs to try to develop other pillars to stand on," said Wolfgang Lickl, portfolio manager at KB-Vermögensverwaltung.</p><p>"The sheer success in diabetes and obesity will make that difficult, but the cardiovascular field makes sense because of the many synergies," he said.</p><p>Following the August trial, Novo has been trying to convince sceptical medical insurers that the long-term benefits of Wegovy are enough to reduce the overall burden on healthcare systems and the cost of treating heart disease in overweight and obese people.</p><p>It expects Wegovy to be approved for sale in China as soon as this year, which would be its second-biggest market after the United States.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4574":"无人驾驶","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","BK4551":"寇图资本持仓","LU1429558221.USD":"Natixis Loomis Sayles US Growth Equity RA USD","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU0823411888.USD":"法巴消费创新基金 Cap","LU1435385759.SGD":"Natixis Loomis Sayles US Growth Equity RA SGD-H","LU0082616367.USD":"摩根大通美国科技A（dist）","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0056508442.USD":"贝莱德世界科技基金A2","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU0719512351.SGD":"JPMorgan Funds - US Technology A (acc) SGD","TSLA":"特斯拉","BK4099":"汽车制造商","BK4548":"巴美列捷福持仓","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU2249611893.SGD":"BNP PARIBAS ENERGY TRANSITION \"CRH\" (SGD) ACC","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","LU2063271972.USD":"富兰克林创新领域基金","BK4550":"红杉资本持仓","LU0823414478.USD":"法巴经典能源转换基金","BK4592":"伊斯兰概念","V":"Visa","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU2326559502.SGD":"Natixis Loomis Sayles US Growth Equity P/A SGD-H","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU1852331112.SGD":"Blackrock World Technology Fund A2 SGD-H","BK4534":"瑞士信贷持仓","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","LU1861215975.USD":"贝莱德新一代科技基金 A2","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1548497426.USD":"安联环球人工智能AT Acc","LU1861558580.USD":"日兴方舟颠覆性创新基金B","LU1861220033.SGD":"Blackrock Next Generation Technology A2 SGD-H","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","NVO":"诺和诺德","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","BK4588":"碎股","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC"},"source_url":"https://news.google.com/rss/articles/CBMilgFodHRwczovL3d3dy5yZXV0ZXJzLmNvbS9idXNpbmVzcy9oZWFsdGhjYXJlLXBoYXJtYWNldXRpY2Fscy9ub3ZvLW5vcmRpc2stcHJlc2VudC1lYXJseS1zdGFnZS10cmlhbC1kYXRhLW5ldy1kaWFiZXRlcy1kcnVnLWludmVzdG9yLW1lZXRpbmctMjAyNC0wMy0wNy_SAQA?oc=5","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2417624937","content_text":"COPENHAGEN, March 7 (Reuters) - Novo Nordisk on Thursday surpassed Tesla Inc in market valuation after the maker of the popular weight-loss drug Wegovy announced positive early trial data for a highly anticipated new obesity drug.Shares surged more than 8% to record highs, shooting Novo Nordisk up in global rankings to the 12th most valuable company from 14 previously, after it told investors a Phase I trial of the pill version of experimental drug amycretin showed participants lost 13.1% of their weight after 12 weeks.That compares to a weight loss of about 6% after 12 weeks and 15% after 68 weeks in trials for Wegovy, its blockbuster obesity drug.Investors welcomed the news as indicating Novo had more in its pipeline beyond its hugely successful Wegovy. Its shares have soared since launching the weekly injections in the United States in 2021.Novo's shares have risen more than three-fold since June 2021 when it launched Wegovy in the United States, last year becoming Europe's most valuable listed company, ahead of LVMH.On Thursday, its market valuation reached $606 billion, ahead of Tesla and Visa, according to LSEG data.\"Novo has made clear that the amycretin molecule likely will form the foundation of the company's rapidly growing pipeline,\" said Guggenheim analyst Seamus Fernandez.Nearly half of Novo's current valuation is based on the company's pipeline of new experimental drugs such as amycretin, according to calculations by Berenberg analysts last week.Markus Manns, a portfolio manager at Union Investment in Germany and Novo shareholder, said the early read-out also compared favourably with other weight-loss pills in development, such as rival Eli Lilly's orforglipron.Lilly's mid-stage trial showed its experimental pill led to 14.7% weight loss after 36 weeks for people who were obese or overweight.The U.S. drugmaker's shares slipped on the upbeat Novo update while shares in Zealand Pharma, which is testing a similar treatment, jumped more than 9%.Wegovy belongs to a class of drugs known as GLP-1 agonists, originally designed to treat type 2 diabetes, that have been shown to reduce food cravings and empty the stomach more slowly.Following the success of these drugs, companies are working on other promising weight-loss therapies such as amycretin which targets a hormone called amylin in the pancreas that affects hunger.Wegovy was the first of a new group of highly effective weight-loss drugs to be launched. Novo and Lilly are so far the leaders in the obesity drug market, forecast by analysts to be worth $100 billion by 2030.HEART DISEASENovo Nordisk Chief Executive Lars Fruergaard Jorgensen said the obesity drug roll-out will be dominated by injectable medicines, with oral versions introduced later in higher-priced markets. Pills require large amounts of active ingredients, making them costly to produce.Earlier in the day, he also announced the company was expanding its focus on diabetes and weight-loss therapies to include cardiovascular disease treatments.The change comes after the drugmaker last August said a large study had shown Wegovy also had a clear cardiovascular benefit, boosting efforts by the company to move Wegovy beyond its image as a lifestyle drug.\"Any company that is so heavily exposed to one therapeutic area needs to try to develop other pillars to stand on,\" said Wolfgang Lickl, portfolio manager at KB-Vermögensverwaltung.\"The sheer success in diabetes and obesity will make that difficult, but the cardiovascular field makes sense because of the many synergies,\" he said.Following the August trial, Novo has been trying to convince sceptical medical insurers that the long-term benefits of Wegovy are enough to reduce the overall burden on healthcare systems and the cost of treating heart disease in overweight and obese people.It expects Wegovy to be approved for sale in China as soon as this year, which would be its second-biggest market after the United States.","news_type":1},"isVote":1,"tweetType":1,"viewCount":43,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
